Results 21 to 30 of about 72,405 (280)
Background: TNF inhibitors are relatively safe drugs, but asymptomatic infliximab-induced high serum creatine kinase (CK) levels have been reported in >30% of patients with inflammatory bowel disease (IBD).
Manuel Sutter +2 more
doaj +1 more source
Background Infliximab is an efficacious therapy for inflammatory bowel disease and may play a role in management of some extraintestinal manifestations.
Daniel J Stein +6 more
doaj +1 more source
Objective: Efficacy, tolerance, and safety of infliximab biosimilar are the same as infliximab reference product (RP) in the management of ankylosing spondylitis (AS) patients previously were on infliximab RP.
Abdulsatar J. Mathkhor +3 more
doaj +1 more source
Systematic review and analysis of evidences on clinical efficacy and cost-effectiveness of biological drugs for the treatment of Ankylosing Spondylitis [PDF]
Technology: Infliximab and comparator biological such as adalimumab, etanercept, golimumab. Conditions: Ankylosing spondylitis (AS) Issue: Infliximab is registered to be used in patients with AS.
Péntek, Márta
core +1 more source
During rheumatoid arthritis (RA) treatment, long-term injection of antitumor necrosis factor α antibodies (anti-TNFα Abs) may induce on-target toxicities, including severe infections (tuberculosis [TB] or septic arthritis) and malignancy.
Yun-Chi Lu +13 more
doaj +1 more source
Background: Ankylosing spondylitis is a rare disease affecting people with hereditary factors. Its treatment includes life style modification and use of drugs such as the biologic agent infliximab or its biosimilar, CT-P13 infliximab.
Mohammed M. Kamil +2 more
doaj +1 more source
AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury
Hepatology, EarlyView.
Robert J. Fontana +6 more
wiley +1 more source
Infliximab therapy in refractory sarcoidosis: a multicenter real-world analysis
Background Infliximab is a monoclonal antibody that binds and neutralizes circulating tumor necrosis factor-alpha, a key inflammatory cytokine in the pathophysiology of sarcoidosis.
Abdullah Sakkat +9 more
doaj +1 more source
Introduction Biosimilar infliximab has the potential for appreciable cost savings compared to its reference biologic, but dose escalation is common and increases costs.
Jeffrey R. Curtis +3 more
doaj +1 more source
Objectives: Many patients with Crohn’s disease on infliximab maintenance therapy have recurrent symptoms despite an initial clinical response. Therefore, concomitant therapies have been studied.
Douglas L. Nguyen +5 more
doaj +1 more source

